AccessibilityHelpAbout Us
Immatics logo

Immatics(NASDAQ) IMTX

Market Cap$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-10%
5 Year-37%
1 Year+30%
1 Month-2%
Premium Feature
Moneyball Superscore
59/100
$8.72
+1.16%
+0.10Today
After hours$8.70-$0.02 (-0.23%)
Immatics last closing stock price
MetricPriceDate
Last closeUSD 8.722026-09-21
Immatics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.16%USD 8.622026-09-14
1 month-2.35%USD 8.932026-08-21
3 month-12.01%USD 9.912026-06-23
Year to date-16.95%USD 10.502025-12-31
1 year+30.15%USD 6.702025-09-19
3 year-25.53%USD 11.712023-09-22
5 year-37.27%USD 13.902021-09-22
Since inception-10.21%USD 9.602018-12-12

Immatics Financials at a Glance

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€41.70M

Net Income (TTM)

-€206.55M

EPS (TTM)

-$1.85

P/E Ratio

-4.66

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$8.72

Volume

305,398.091

Open

$8.76

Previous Close

$8.72

Daily Range

$8.58 - $8.87

52-Week Range

$6.55 - $12.41

Estimated Earnings Date

Nov 17, 2026

IMTX News

Scientists smiling and shaking hands

Why Immatics Stock Is Soaring Today

Keith SpeightsMay 2, 2023
GettyImages-943401146

Why Immatics Stock Is Soaring Today

Prosper Junior BakinyMar 17, 2021

IMTX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immatics

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T-cell receptor (TCR) based immunotherapies to treat cancer. The company specializes in targeted immunotherapies for solid tumors, utilizing innovative approaches such as adoptive cell therapies and antibody-like TCR Bispecifics.

Products and Services
  • ACTengine™ portfolio with candidates in Phase I clinical trials
  • Preclinical TCR Bispecifics targeting cancer testis antigens
  • Strategic partnerships for novel adoptive cell therapies
Growth Outlook
  • Recent revenue of €9.14 million in Q2 2026, showing growth potential
  • Strong cash position with €232 million in cash and equivalents
  • Ongoing clinical trials may lead to significant advancements in cancer treatment
Financial Highlights
  • Net income of -€62.49 million in Q2 2026, reflecting ongoing investment in R&D
  • Current ratio of 7.54 indicates strong liquidity position
  • Trailing twelve months (TTM) revenue of €39.5 million, showcasing growth trajectory
Immatics N.V. is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company's ACTengine™ portfolio includes several candidates currently in Phase I clinical trials, which may provide promising treatment options for patients with solid tumors. The strategic partnerships with leading organizations enhance its research capabilities and market reach. Financially, Immatics has demonstrated a solid cash position, which is crucial for funding ongoing research and development efforts. Despite reporting a net loss, the revenue growth in recent quarters indicates a positive trend. The high current ratio suggests that the company is well-equipped to meet its short-term obligations, providing a buffer as it continues to invest heavily in its clinical programs. Overall, Immatics N.V. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the area of cancer immunotherapy. The company's innovative approach and strong financial position may lead to significant advancements in treatment options for patients in need.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

407

CEO

Harpreet Singh-Jasuja, PhD

Website

www.immatics.com

Headquarters

Tübingen, BW 72076, DE

IMTX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-543.79%

Net Income Margin

-495.27%

Return on Equity

-47.04%

Return on Capital

-36.44%

Return on Assets

-42.54%

Earnings Yield

-21.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

149.64M

Volume

305.40K

Avg. Volume

497.78K

Financials (TTM)

Gross Profit

€41.70M

Operating Income

-€226.78M

EBITDA

-€193.84M

Operating Cash Flow

-€206.27M

Capital Expenditure

-€3.68M

Free Cash Flow

-€209.95M

Cash & ST Invst.

€393.19M

Total Debt

€14.60M

Immatics Performance Analysis

Immatics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 181,640,942342.1%
20232023-12-31EUR 58,376,999-67.9%
20242024-12-31EUR 168,565,279188.8%
20252025-12-31EUR 54,471,943-67.7%
Immatics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.5%
Q42025-12-31281.0%
Q12026-03-31-61.5%
Q22026-06-3020.1%
Immatics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.57N/A
20232023-12-31EUR -1.27N/A
20242024-12-31EUR 0.15N/A
20252025-12-31EUR -1.81N/A
Immatics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.6%
Q42025-12-3133.3%
Q12026-03-31-53.6%
Q22026-06-30-7.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€9.14M

+93.0%

Gross Profit

€9.14M

+93.0%

Gross Margin

100.00%

N/A

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.83M

N/A

Employees

704

N/A

Net Income

-€62.49M

+11.2%

EBITDA

-€59.51M

+12.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€393.19M

-17.8%

Total Debt

€14.60M

-14.7%

Accounts Receivable

€6.66M

+128.8%

Inventory

€0.00

N/A

Long Term Debt

€11.94M

-15.4%

Short Term Debt

€2.66M

-11.3%

Return on Assets

-42.54%

N/A

Return on Invested Capital

-52.91%

N/A

Free Cash Flow

-€62.08M

-52.9%

Operating Cash Flow

-€61.20M

-56.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRMLTourmaline Bio, Inc.
$47.98+0.00%
CVACCureVac N.V.
$4.66+0.00%
SNDXSyndax Pharmaceuticals, Inc.
$18.07+2.55%
INBXInhibrx Biosciences Inc.
$112.04+2.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About IMTX

What is the current price of Immatics?

Immatics is trading at $8.72 per share.

What is the 52-week range for Immatics?

Over the past 52 weeks, Immatics has traded between $6.55 and $12.41.

How much debt does Immatics have?

As of the most recent reporting period, Immatics reported total debt of €16.70M.

How much cash does Immatics have on hand?

Immatics reported €265.77M in cash and cash equivalents in its most recent financial results.

What is Immatics’s dividend yield?

Immatics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services